Professor Klaus G Parhofer

Professor Klaus G Parhofer

Ludwig Maximilians University, Munich (Germany)

Klaus Parhofer is a Professor of Endocrinology and Metabolism at the University in Munich, Germany, with a special focus on metabolic diseases.

Presentations Articles

Panel discussion and Q&A

Event: ESC Congress 2024

Topic: Lipid-Lowering Agents

Session: Cholesterol lowering in high cardiovascular risk patients with comorbidities: closing gaps and future opportunities

Access

Unmet needs: real-world evidence reveals treatment gaps in patients with diabetes and obesity

Event: ESC Congress 2024

Topic: Lipid-Lowering Agents

Session: Cholesterol lowering in high cardiovascular risk patients with comorbidities: closing gaps and future opportunities

Access

Clinical experience with add-on oral therapy: patient cases..

Event: ESC Congress 2022

Topic: Drug therapy

Session: Optimising the lipid management of high and very high cardiovascular risk patients

Access

Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017-2020

Event: ESC Congress 2022

Topic: Hospital Information Systems, Electronic Medical Records, Clinical Decision Support

Session: Digital health innovation: from artificial intelligence to clinical decision support

Access

When and how to treat hypertriglyceridemia.

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacology and Pharmacotherapy

Session: Lipid lowering beyond LDL-cholesterol and statins

Access

PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data

Event: ESC Congress 2018

Topic: Drug therapy

Session: Preventive cardiology / Lipids

Access

The ODYSSEY ESCAPE study: rationale, design, patient characteristics at baseline, and final study data

Event: ESC Congress 2016

Topic: Lipids

Session: Lipids and coronary artery disease

Access

ESC 365 is supported by

Explore sponsored resources

Professor Klaus G Parhofer

Biography

Contributor content

Panel discussion and Q&A

Unmet needs: real-world evidence reveals treatment gaps in patients with diabetes and obesity

Clinical experience with add-on oral therapy: patient cases..

Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017-2020

When and how to treat hypertriglyceridemia.

PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data

The ODYSSEY ESCAPE study: rationale, design, patient characteristics at baseline, and final study data

ESC 365 is supported by

Professor Klaus G Parhofer Follow

Biography

Contributor content

Panel discussion and Q&A

Unmet needs: real-world evidence reveals treatment gaps in patients with diabetes and obesity

Clinical experience with add-on oral therapy: patient cases..

Estimating prevalence and characteristics of statin intolerance among high and very high cardiovascular risk patients in Germany between 2017-2020

When and how to treat hypertriglyceridemia.

PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: final study and cardiovascular subgroup data

The ODYSSEY ESCAPE study: rationale, design, patient characteristics at baseline, and final study data

ESC 365 is supported by

Professor Klaus G Parhofer